Letters to the Editor
Vol. 93 No. 3 (2021)
https://doi.org/10.4081/aiua.2021.3.370
Stereotactic Body Radiation Therapy (SBRT) for prostate cancer: Preliminary results of toxicity
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: 18 April 2021
Accepted: 8 March 2026
Published: 4 October 2021
Accepted: 8 March 2026
Published: 4 October 2021
1030
Views
683
Downloads
To the Editor,
Prostate cancer is the second most common cancer in men in Morocco after lung cancer. External radiotherapy (RTE) is a curative therapeutic option for localized prostate cancer, However the conventional RTE remains a long treatment (7- 8 weeks, 5 days a week) which is demanding for patients and make difficult to manage the waiting lists. The development of imaging and irradiation techniques over the last decades has allowed a high precision in the delivery of the dose to the target organ and a better protection of the organs at risk (OAR), which has encouraged the hypo fractionated irradiation of localized prostate cancer, especially after the results of radiobiology studies that suggested a low report a/b for the prostate.
Downloads
Download data is not yet available.
Katz AJ, Kang J. Quality of life and toxicity after SBRT for organ-confined prostate cancer, a 7-year study. Front Oncol. 2014; 4:301. DOI: https://doi.org/10.3389/fonc.2014.00301
Widmark A, Gunnlaugsson A, Beckman L, et al. Ultrahypofractionation for prostate cancer: Outcome from the Scandinavian phase 3 HYPORT-PC trial. Lancet 2019; 394(10196):385-395. DOI: https://doi.org/10.1016/S0140-6736(19)31131-6
Van As NJ, Brand D, Tree A, et al. PACE: Analysis of acute toxicity in PACE-B, an international phase III randomized controlled trial comparing stereotactic body radiotherapy (SBRT) to conventionally fractionated or moderately hypofractionated external beam radiotherapy (CFMHRT) for localized prostate cancer (LPCa). J Clin Oncol. 2019; 37(Suppl 7):1-1. DOI: https://doi.org/10.1200/JCO.2019.37.7_suppl.1
Noël G, Antoni D, Barillot I, et al. Délinéation des organes à risque et contraintes dosimétriques. Cancer/Radiothérapie. 2016; 20 Suppl:S36-60. DOI: https://doi.org/10.1016/j.canrad.2016.07.032
Benedict SH, Yenice KM, Followill D, et al. Stereotactic body radiation therapy: The report of TG101. Med Phys. 2010; 37:4078-101. DOI: https://doi.org/10.1118/1.3438081
Hoffman KE, Voong KR, Levy LB, et al. Randomized trial of hypofractionated, dose-escalated, intensity- modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. J Clin Oncol. 2018; 36:2943-2949. DOI: https://doi.org/10.1200/JCO.2018.77.9868
Zaorsky NG, Palmer JD, Hurwitz MD, et al. What is the ideal radiotherapy dose to treat prostate cancer? A meta-analysis of biologically equivalent dose escalation Radiother Oncol. 2015; 115:295-300 DOI: https://doi.org/10.1016/j.radonc.2015.05.011
Aluwini S, Pos F, Schimmel E, et al. Hypo fractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): Late toxicity results from a randomized, non- inferiority, phase 3 trial. Lancet Oncol. 2016; 17:464-474 DOI: https://doi.org/10.1016/S1470-2045(15)00567-7
Dearnaley D, Syndikus I, Mossop H, et al. Conventional versus hypo fractionated high-dose intensity- modulated radiotherapy for prostate cancer: 5- year outcomes of the randomized, non- inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016; 17:1047-1060. DOI: https://doi.org/10.1016/S1470-2045(16)30102-4
Hoffman KE, Skinner H, Pugh TJ, et al. Patient reported urinary, bowel, and sexual function after hypofractionated intensity-modulated radiation therapy for prostate cancer: Results from a randomized trial. J Clin Oncol. 2018; 41:558-567. DOI: https://doi.org/10.1097/COC.0000000000000325
Madsen BL, Hsi RA, Pham HT, et al. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys. 2007; 67:1099-105. DOI: https://doi.org/10.1016/j.ijrobp.2006.10.050
Jackson WC, Silva J, Hartman HE, et al. Stereotactic body radiation therapy for localized prostate cancer: a systematic review and metaanalysis of over 6,000 patients treated on prospective studies. Int J Radiat Oncol Biol Phys. 2019; 104:778-789. DOI: https://doi.org/10.1016/j.ijrobp.2019.03.051
Pan HY, Jiang J, Hoffman KE, et al. Comparative toxicities and cost of intensity-modulated radiotherapy, proton radiation, and stereotactic body radiotherapy among younger men with prostate cancer. ,J Clin Oncol. 2018; 36:1823-1830. DOI: https://doi.org/10.1200/JCO.2017.75.5371
Morrison K, Tree A, Khoo V, et al. The PACE trial: International randomised study of laparoscopic prostatectomy vs. stereotactic body radiotherapy (SBRT) and standard radiotherapy vs. SBRT for early stage organ- confined prostate cancer. J Clin Oncol. 2018; 36(Suppl 6):TPS153-TPS153. DOI: https://doi.org/10.1200/JCO.2018.36.6_suppl.TPS153
Quon HC, Ong A, Cheung P, et al. Once-weekly versus every-other-day stereotactic body radiotherapy in patients with prostate cancer (PATRIOT): a phase 2 randomized trial. Radiother Oncol. 2018; 127:206-212. DOI: https://doi.org/10.1016/j.radonc.2018.02.029
How to Cite
Stereotactic Body Radiation Therapy (SBRT) for prostate cancer: Preliminary results of toxicity. (2021). Archivio Italiano Di Urologia E Andrologia, 93(3), 370-372. https://doi.org/10.4081/aiua.2021.3.370
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.